Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and ...

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with ...

The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has changed dramatically over the past decade, resulting in more therapeutic options for various stages of relapse. In a ...

Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival (PFS) and the overall response rate (ORR) in patients with ...